TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 35671201
Drug: Fixed-dose tremelimumab
Normalized name: tremelimumab
DrugBank: Tremelimumab (DB11771)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fixed-dose tremelimumab 75 mg (Q4W for 4 doses) plus durvalumab 1500 mg (Q4W for 13 doses)
Study: 35671201
Drug: Tremelimumab 10
Normalized name: TREMELIMUMAB
DrugBank: Tremelimumab (DB11771)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tremelimumab 10 mg/kg (Q4W/Q12W)
Study: 35672037
Drug: Patient treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patient treatment choices
Study: 35672688
Drug: NEIVATECH virtual
Approvals — FDA: no, EMA: no, PMDA: no
Description: NEIVATECH virtual reality system (group A) - 18 half-hour in-office therapy sessions for 3 months
Study: 35672754
Drug: Surgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical treatment after Monteggia injury
Study: 35672923
Drug: Cladribine tablets
Normalized name: Cladribine
DrugBank: Cladribine (DB00242)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Cladribine tablets (dosage and duration not available)
Study: 35674480
Drug: Lenvatinib (dosage
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lenvatinib (dosage not specified, administered daily)
Study: 35674880
Drug: Tirzepatide (5-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tirzepatide (5-mg subcutaneous dose)
Study: 35675370
Drug: BNT162b2 (mRNA
Approvals — FDA: no, EMA: no, PMDA: no
Description: BNT162b2 (mRNA vaccine)
Study: 35675590
Drug: Ponatinib (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ponatinib (30 mg/d) with standard induction and consolidation chemotherapy followed by allogeneic hematopoietic stem cell transplant (alloHSCT)
Study: 35675590
Drug: Ponatinib with
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ponatinib with chemotherapy followed by alloHSCT
Study: 35676017
Drug: Multivariate model
Normalized name: polysaccharide iron complex
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multivariate model derived from high dimensional data set including epidemiological, psychometric, quantitative sensory, brain imaging and biological information
Study: 35676062
Drug: Cetuximab and
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cetuximab and nivolumab combination therapy
Study: 35677040
Drug: Antiviral treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antiviral treatment during pregnancy
Study: 35677040
Drug: No antiviral
Approvals — FDA: no, EMA: no, PMDA: no
Description: No antiviral treatment during pregnancy
Study: 35677980
Drug: Vaccine-induced immune
Normalized name: Vaccinia Immune Globulin
DrugBank: Human vaccinia virus immune globulin (DB14112)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vaccine-induced immune thrombotic thrombocytopenia (VITT) cases in the first 5 months of 2021
Study: 35678128
Drug: Centralized, pharmacy-led
Approvals — FDA: no, EMA: no, PMDA: no
Description: Centralized, pharmacy-led penicillin allergy evaluation and single-dose oral challenge
Study: 35678233
Drug: Mocetinostat 70-mg
Normalized name: Mocetinostat
DrugBank: Mocetinostat (DB11830)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mocetinostat 70-mg with nivolumab and ipilimumab
Study: 35678233
Drug: Mocetinostat 50-mg
Normalized name: Mocetinostat
DrugBank: Mocetinostat (DB11830)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mocetinostat 50-mg with nivolumab and ipilimumab
Study: 35678233
Drug: Mocetinostat (both
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mocetinostat (both doses)
Study: 37311429
Drug: Omnipod 5
Normalized name: RESERVOIR,OMNIPOD 5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Omnipod 5 Automated Insulin Delivery System
Study: 35679476
Drug: axi-cel (autologous
Approvals — FDA: no, EMA: no, PMDA: no
Description: axi-cel (autologous anti-CD19 chimeric antigen receptor T-cell therapy)
Study: 35680043
Drug: Pembrolizumab 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab 200 mg Q3W for 35 cycles or until disease progression or unacceptable toxicity
Study: 35680387
Drug: Glucocorticoids (GC)
Normalized name: GCS-100
DrugBank: GCS-100 (DB17566)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucocorticoids (GC) doses of <5 mg prednisone equivalent per day
Study: 35680387
Drug: Glucocorticoids (GC)
Normalized name: GCS-100
DrugBank: GCS-100 (DB17566)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucocorticoids (GC) doses of ≥5 mg/day
Study: 35680387
Drug: Glucocorticoids (GC)
Normalized name: GCS-100
DrugBank: GCS-100 (DB17566)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucocorticoids (GC) doses of exactly 5 mg/day
Study: 35680387
Drug: Glucocorticoids (GC)
Normalized name: GCS-100
DrugBank: GCS-100 (DB17566)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucocorticoids (GC) doses of >7.5 mg/day in rheumatoid arthritis (RA) patients
Study: 35680387
Drug: Glucocorticoids (GC)
Normalized name: GCS-100
DrugBank: GCS-100 (DB17566)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucocorticoids (GC) doses of ≤5 mg/day
Study: 35680387
Drug: Glucocorticoids (GC)
Normalized name: GCS-100
DrugBank: GCS-100 (DB17566)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucocorticoids (GC) doses of >7.5 mg/day in RA patients with moderate to high disease activity
Study: 35681574
Drug: Neoadjuvant−adjuvant pertuzumab−trastuzumab-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant−adjuvant pertuzumab−trastuzumab-based therapy (Cohort A: dose-dense doxorubicin and cyclophosphamide followed by paclitaxel; Cohort B: 5-fluorouracil, epirubicin, cyclophosphamide followed by docetaxel)
Study: 35683592
Drug: Cell therapy
Normalized name: hRPE cell therapy
DrugBank: ASP-7317 (DB18549)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cell therapy (intracoronary cell-based therapy)
Study: 35685504
Drug: Oral Anticoagulation
Normalized name: monitoring agent for oral anticoagulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Anticoagulation (OAC) therapy
Study: 35685504
Drug: No Oral
Normalized name: Beano Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: No Oral Anticoagulation (OAC) therapy
Study: 37304043
Drug: Ranibizumab 2.0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ranibizumab 2.0 mg
Study: 35687781
Drug: Triple guideline-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple guideline-based medical therapy (GBMT)
Study: 35687781
Drug: Dual guideline-based
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual guideline-based medical therapy (GBMT)
Study: 35687781
Drug: Single guideline-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single guideline-based medical therapy (GBMT)
Study: 35687781
Drug: No guideline-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: No guideline-based medical therapy (GBMT)
Study: 35688469
Drug: DPC score
Normalized name: fecal microbiota spores, live Oral Capsule [Vowst]
Approvals — FDA: no, EMA: no, PMDA: no
Description: DPC score (0-15 points) based on dialysis duration, pretransplant intact parathyroid hormone, and serum calcium level
Study: 35688554
Drug: DuoBody-CD40×4-1BB with
Approvals — FDA: no, EMA: no, PMDA: no
Description: DuoBody-CD40×4-1BB with PD-1 blocking antibodies
Study: 35688679
Drug: Sunitinib 50
Normalized name: sunitinib 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib 50 mg plus erlotinib (dose levels: 50, 100, 150 mg daily)
Study: 35688802
Drug: AZD4547 administered
Normalized name: no vaccine administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD4547 administered with anastrozole or letrozole
Study: 35689544
Drug: Alvocidib administered
Normalized name: Alvocidib
DrugBank: Alvocidib (DB03496)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alvocidib administered in combination with cytarabine and mitoxantrone (ACM) for R/R AML
Study: 35689544
Drug: Alvocidib administered
Normalized name: Alvocidib
DrugBank: Alvocidib (DB03496)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alvocidib administered in combination with cytarabine/daunorubicin (A + 7 + 3) for newly diagnosed AML
Study: 35689597
Drug: Upper airway
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Upper airway stimulation (UAS) treatment
Study: 35689737
Drug: Apremilast 30
Normalized name: apremilast 30 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Apremilast 30 mg twice daily for 16 weeks in addition to existing topical therapy
Study: 35690072
Drug: Cabozantinib 40
Normalized name: cabozantinib 40 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cabozantinib 40 mg per day and intravenous atezolizumab 1200 mg once every 3 weeks
Study: 35691028
Drug: Recently approved
Normalized name: glucose
DrugBank: Dextrose, unspecified form (DB09341)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Recently approved antibiotics positioning in SOT setting.
Study: 35691544
Drug: CC-99677, a
Approvals — FDA: no, EMA: no, PMDA: no
Description: CC-99677, a selective targeted covalent MK2 inhibitor
Study: 35693874
Drug: Meningococcal vaccine
Normalized name: Meningococcal vaccines
Approvals — FDA: no, EMA: no, PMDA: no
Description: Meningococcal vaccine
Study: 35694680
Drug: Potassium-ferrate based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Potassium-ferrate based topical hemostasis disc
Study: 35695002
Drug: Bevacizumab and
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab and FOLFIRI in combination with daily oral G-NLC (ginsenoside-modified nanostructured lipid carrier containing curcumin)
Study: 35695332
Drug: Clopidogrel Discontinuation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel Discontinuation Group
Study: 35695332
Drug: Non-Clopidogrel Discontinuation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-Clopidogrel Discontinuation Group
Study: 35695563
Drug: Entrectinib in
Normalized name: Product containing entrectinib in oral dose form (medicinal product form)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Entrectinib in combination with endocrine therapy
Study: 35695646
Drug: Antidepressant combinations
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antidepressant combinations
Study: 35695646
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of baseline SI and insomnia
Study: 35696157
Drug: 10 mg/ml
Normalized name: urea 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/ml protonated nicotine at 15 W
Study: 35696157
Drug: 10 mg/ml
Normalized name: urea 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/ml protonated nicotine at 30 W
Study: 35696157
Drug: 15 mg/ml
Normalized name: phenol 15 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg/ml protonated nicotine at 15 W
Study: 35696157
Drug: 15 mg/ml
Normalized name: phenol 15 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg/ml protonated nicotine at 30 W
Study: 35696157
Drug: 30 mg/ml
Normalized name: urea 30 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/ml protonated nicotine at 15 W
Study: 35696157
Drug: 30 mg/ml
Normalized name: urea 30 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 mg/ml protonated nicotine at 30 W
Study: 35696702
Drug: Neoadjuvant cetuximab
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Neoadjuvant cetuximab followed by concurrent radiotherapy with cetuximab 250 mg/m2/cisplatin 40 mg/m2 (DL1)
Study: 35696702
Drug: Radiotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy with cetuximab 200 mg/m2 and cisplatin 30 mg/m2 (DL2)
Study: 35696702
Drug: Radiotherapy with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy with cetuximab 250 mg/m2 and cisplatin 30 mg/m2 (DL3)
Study: 35697255
Drug: Rivaroxaban underdose
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rivaroxaban underdose (10 mg/d)
Study: 35697255
Drug: Rivaroxaban standard-dose
Normalized name: Rivaroxaban
DrugBank: Rivaroxaban (DB06228)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rivaroxaban standard-dose (15 mg/d)
Study: 35697332
Drug: Vebicorvir (VBR)
Normalized name: Vebicorvir
DrugBank: Vebicorvir (DB18784)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vebicorvir (VBR) 300 mg + Entecavir (ETV) 0.5 mg
Study: 35697332
Drug: Placebo (PBO)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (PBO) + Entecavir (ETV) 0.5 mg
Study: 35697729
Drug: Fish oil
Normalized name: Fish oil
DrugBank: Fish oil (DB13961)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fish oil emulsion (FO) adjunct to 3+7 chemotherapy
Study: 35698155
Drug: DEXA+ (dexamethasone
Approvals — FDA: no, EMA: no, PMDA: no
Description: DEXA+ (dexamethasone 6 mg/day intravenous for 10 days)
Study: 35698232
Drug: Bromocriptine (pre-treatment)
DrugBank: Bromocriptine (DB01200)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bromocriptine (pre-treatment)
Study: 39343385
Drug: Dupilumab 300
Normalized name: dupilumab 300 MG in 2 ML Auto-Injector
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dupilumab 300 mg every 2 weeks for 52 weeks
Study: 35700000
Drug: Preprocedural immersive
Normalized name: OCTOCRYLENE 10 g in 100 g / HOMOSALATE 10 g in 100 g / AVOBENZONE 3 g in 100 g / OCTISALATE 4.5 g in 100 g TOPICAL LOTION [Eucerin Face immersive Hydration]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preprocedural immersive virtual reality (IVR) game preparation (IMAGINE)
Study: 37616032
Drug: NiteCAPP CARES
Approvals — FDA: no, EMA: no, PMDA: no
Description: NiteCAPP CARES (web-based cognitive behavioral therapy for insomnia)
Study: 35700142
Drug: Finerenone 10
Normalized name: finerenone 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finerenone 10 mg or 20 mg plus empagliflozin 10 mg
Study: 35700142
Drug: Empagliflozin 10
Normalized name: empagliflozin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Empagliflozin 10 mg alone
Study: 35700142
Drug: Finerenone 10
Normalized name: finerenone 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Finerenone 10 mg or 20 mg alone
Study: 35701541
Drug: RBD-based SARS-CoV-2
Normalized name: RBD SARS-CoV-2 HBsAg VLP vaccine
DrugBank: Receptor binding domain (RBD) SARS-CoV-2 (COVID-19) hepatitis B surface antigen (HBsAg) virus-like particle (VLP) vaccine (DB16431)
Approvals — FDA: no, EMA: no, PMDA: no
Description: RBD-based SARS-CoV-2 mRNA vaccine, specific dosage and duration not available
Study: 35703113
Drug: sasanlimab (immune
Approvals — FDA: no, EMA: no, PMDA: no
Description: sasanlimab (immune checkpoint inhibitor) combined with stereotactic body radiation therapy (SBRT)
Study: 35703113
Drug: sasanlimab (immune
Approvals — FDA: no, EMA: no, PMDA: no
Description: sasanlimab (immune checkpoint inhibitor)
Study: 35704034
Drug: Reproductive hormones
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Reproductive hormones (LH, FSH, inhibin B, AMH, E1, E2, SHBG) measured during minipuberty
Study: 35704795
Drug: T-cell-dependent vaccine
Normalized name: Fcrh5/cd3 t cell dependent bispecific antibody bfcr4350a
DrugBank: Cevostamab (DB18374)
Approvals — FDA: no, EMA: no, PMDA: no
Description: T-cell-dependent vaccine against Haemophilus influenzae type b (Hib)
Study: 35704795
Drug: T-cell-independent pneumococcal
Normalized name: Virus Specific T-Cell
DrugBank: Virus Specific T-Cell (DB15735)
Approvals — FDA: no, EMA: no, PMDA: no
Description: T-cell-independent pneumococcal polysaccharide vaccine (PPSV)
Study: 35705788
Drug: Levonorgestrel-releasing intrauterine
Normalized name: levonorgestrel Intrauterine System
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levonorgestrel-releasing intrauterine system (LNG-IUS) 52 mg
Study: 35707873
Drug: Tezepelumab 210
Normalized name: TEZEPELUMAB 210 mg in 1.9 mL SUBCUTANEOUS INJECTION, SOLUTION [TEZSPIRE]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tezepelumab 210 mg SC Q4W
Study: 35708131
Drug: Camp Kidpower
Approvals — FDA: no, EMA: no, PMDA: no
Description: Camp Kidpower intervention (CC training)
Study: 35708166
Drug: VR-assisted cognitive
Normalized name: Prostin VR
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: VR-assisted cognitive behavioural therapy for psychosis (CBTp)
Study: 35708466
Drug: Flunarizine treatment
Normalized name: flunarizine
DrugBank: Flunarizine (DB04841)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flunarizine treatment for 3 months
Study: 35708744
Drug: Health apps
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Health apps related to medication, treatments, and follow-up care
Study: 35708763
Drug: Distribution of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Distribution of self-diagnosis and self-treatment kits after training by health mediators (facilitators).
Study: 35708763
Drug: Mobile data
Normalized name: Chamaemelum nobile extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mobile data collection using Android tablets with ODK Collect.
Study: 35710741
Drug: Bempegaldesleukin in
Normalized name: Bempegaldesleukin
DrugBank: Bempegaldesleukin (DB15140)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bempegaldesleukin in combination with nivolumab
Study: 35711259
Drug: Pipeline Embolization
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pipeline Embolization Device (PED) therapy
Study: 35712486
Drug: Sintilimab (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sintilimab (200 mg) and Anlotinib (12 mg once daily on days 1 to 14 every 3 weeks)
Study: 35712797
Drug: Nirmatrelvir/ritonavir (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nirmatrelvir/ritonavir (100 mg nirmatrelvir with 100 mg ritonavir)
Study: 35713209
Drug: Weekly Calendar
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Weekly Calendar Planning Activity (WCPA)
Study: 35713509
Drug: Early oral
Normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Early oral β-blocker therapy (users)
Study: 35713509
Drug: High-dose β-blocker
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose β-blocker therapy (metoprolol-equivalent dose ≥50 mg/day)
Study: 35713509
Drug: Low-dose β-blocker
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose β-blocker therapy (metoprolol-equivalent dose <50 mg/day)
Study: 35714311
Drug: Direct-acting antivirals
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Direct-acting antivirals (DAAs) - 17 ledipasvir/sofosbuvir, 8 sofosbuvir plus ribavirin, 15 sofosbuvir/velpatasvir
Study: 35714349
Drug: Insulin Replacement
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin Replacement
Study: 35714431
Drug: Prolonged dual
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prolonged dual antiplatelet therapy (DAPT) for 12-24 months
Study: 35714431
Drug: Standard dual
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard dual antiplatelet therapy (DAPT) for 6-12 months
Study: 35714666
Drug: MRI-guided focused
Normalized name: Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MRI-guided focused ultrasound focal therapy
Study: 35714735
Drug: AAV2-hCHM subretinal
Normalized name: AAV2-hRPE65v2
DrugBank: Voretigene neparvovec (DB13932)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AAV2-hCHM subretinal injections
Study: 35715340
Drug: Stereotactic body
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stereotactic body radiotherapy (SBRT) with a median dose of 36.25 Gy in five fractions
Study: 35715627
Drug: Cobimetinib (tablet)
DrugBank: Cobimetinib (DB05239)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cobimetinib (tablet) at a recommended Phase II dose (RP2D) of 0.8 mg/kg
Study: 35715627
Drug: Cobimetinib (suspension)
DrugBank: Cobimetinib (DB05239)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Cobimetinib (suspension) at a recommended Phase II dose (RP2D) of 1.0 mg/kg
Study: 35715627
Drug: Cobimetinib (tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cobimetinib (tablet and suspension)
Study: 35715631
Drug: Physical activity
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Physical activity dose classification
Study: 35715801
Drug: Seraph® 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Seraph® 100 Microbind® Affinity Blood Filter treatment
Study: 35715980
Drug: Choline and
Normalized name: Choline and glycerin only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Choline and L/Z intake interaction
Study: 35715980
Drug: Choline, L/Z,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Choline, L/Z, and DHA interaction
Study: 35715980
Drug: L/Z intake
Approvals — FDA: no, EMA: no, PMDA: no
Description: L/Z intake
Study: 35715980
Drug: Choline and
Normalized name: Choline and glycerin only product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Choline and L/Z interaction
Study: 35715980
Drug: L/Z and
Approvals — FDA: no, EMA: no, PMDA: no
Description: L/Z and DHA interaction
Study: 35716331
Drug: High broad-spectrum
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High broad-spectrum sunscreen medical device (MD) containing UVB and UVA filters and 1% ectoin, applied at a dosage of 2 mg/cm².
Study: 35716332
Drug: Difamilast 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Difamilast 1% ointment (adults)
Study: 35716332
Drug: Difamilast 0.3%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Difamilast 0.3% ointment (pediatrics)
Study: 35716332
Drug: Difamilast 1%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Difamilast 1% ointment (pediatrics)
Study: 35717027
Drug: Guadecitabine (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guadecitabine (30 mg/m²) in combination with pembrolizumab
Study: 35717147
Drug: Monthly questionnaires
Normalized name: tobramycin
DrugBank: Tobramycin (DB00684)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Monthly questionnaires on sleep and parental sleep
Study: 35717608
Drug: Insulin resistance
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Insulin resistance (IR) and beta-cell dysfunction (BCD)
Study: 35719001
Drug: 60-minute dosing
Normalized name: TAGETES MINUTA FLOWER OIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60-minute dosing interval
Study: 35719001
Drug: 30-minute dosing
Normalized name: TAGETES MINUTA FLOWER OIL
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30-minute dosing interval
Study: 35719139
Drug: BOSB (bean
Approvals — FDA: no, EMA: no, PMDA: no
Description: BOSB (bean and oats snack bar), 50 g per day
Study: 35719960
Drug: Nab-paclitaxel (100mg/m)
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Nab-paclitaxel (100mg/m) + phenelzine (60mg daily)